Xi Lei

About

Research topic:

The biochemical mechanism underlying self-sustaining control of activity of immune evasion machinery in pancreatic ductal adenocarcinoma cells.

Qualifications:

Master degree in thoracic surgery,2019-2022

Bachelor degree (M.D) in clinical medicine,2013-2018

Research interests

Since I worked at hospital before, my study used to focus on lung cancer treatment and also on tumor microenvironment in lung cancer due to my experience in lung cancer institute. But I also have interests in the interplay between immune cells and cancer cells in tumor environment. Currently, I am studying crosstalk between different immune check points, like gal-9, tim-3 and vista, with the supervision of Dr Vadim trying to find the underlying mechanism of cancer immune evasion.

Supervision

Supervisors: Dr Vadim Sumbayev and Dr Maxwell Casely-Hayford

Research Group: Chemistry and Drug Delivery

Professional

Publications:

1. Abooali M, Schlichtner S, Lei X, Aliu N, Ruggiero S, Loges S, Ziegler M, Hertel F, Volckmar AL, Stenzinger A, Christopoulos P, Thomas M, Klenova E, Meyer NH, Boussios S, Heaton N, Zen Y, Zamalloa A, Chokshi S, Urbani L, Richard S, Kirubendran K, Hussain R, Siligardi G, Cholewa D, Berger SM, Yasinska IM, Fasler-Kan E, Sumbayev VV. Intracellular and extracellular activities of V-domain Ig-containing suppressor of T cell activation (VISTA) modulated by immunosuppressive factors of tumour microenvironment. Cancer Lett. 2025 Apr 28;616:217581. doi: 10.1016/j.canlet.2025.217581. Epub 2025 Feb 20. PMID: 39983894.
2. Lei X, Li T, Mao F, Ren F, Tang Q, Cao W, Zu L, Xu S. Lobe-specific analysis of perioperative chemotherapy for non-small cell lung cancer patients. Cancer Med. 2023 Aug;12(16):16896-16905. doi: 10.1002/cam4.6319. Epub 2023 Jul 5. PMID: 37403701; PMCID: PMC10501251.
3. Cao W, Yu H, Zhu S, Lei X, Li T, Ren F, Zhou N, Tang Q, Zu L, Xu S. Clinical significance of preoperative neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in the prognosis of resected early-stage patients with non-small cell lung cancer: A meta-analysis. Cancer Med. 2023 Mar;12(6):7065-7076. doi: 10.1002/cam4.5505. Epub 2022 Dec 8. PMID: 36480232; PMCID: PMC10067053.
4. Xu S, Li X, Ren F, He J, Zhao S, Wang Y, Ren D, Zhu S, Lei X, Chen G, Chen J. Sublobar Resection Versus Lobectomy for Early-Stage Pulmonary Carcinoid Tumors ≤3 cm in Size: A SEER Population-Based Study. Ann Surg. 2022 Dec 1;276(6):e991-e999. doi: 10.1097/SLA.0000000000004593. Epub 2020 Nov 13. PMID: 33196487.
5. Lei X, Zhou N, Zhang H, Li T, Ren F, Zhang B, Li X, Zu L, Song Z, Xu S. Lobe-Specific Analysis of Sublobar Lung Resection for NSCLC Patients with Tumors ≤ 2 cm. Cancers (Basel). 2022 Jul 4;14(13):3265. doi: 10.3390/cancers14133265. PMID: 35805037; PMCID: PMC9265391.
6. Lei X, Zhu S, Ren D, Ren F, Li T, Zhou N, Li S, Shi T, Zu L, Song Z, Chalubinska-Fendler J, Denis MG, Bernicker EH, Thomas de Montpréville V, Jiang R, Xu S. Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature. Transl Lung Cancer Res. 2022 Jun;11(6):1176-1184. doi: 10.21037/tlcr-22-394. PMID: 35832448; PMCID: PMC9271430.
7. Zhao S, Zhu S, Lei X, Xu D, Shi T, Chen Q, Ren F, Chen G, Huang D, Xu S. Use of crizotinib as neoadjuvant therapy for non-small cell lung cancers patient with ROS1 rearrangement: A case report. Thorac Cancer. 2021 Oct;12(20):2815-2818. doi: 10.1111/1759-7714.14112. Epub 2021 Aug 17. PMID: 34405544; PMCID: PMC8520795.
8. Xu S, Li X, Zhang H, Zu L, Yang L, Shi T, Zhu S, Lei X, Song Z, Chen J. Frequent Genetic Alterations and Their Clinical Significance in Patients With Thymic Epithelial Tumors. Front Oncol. 2021 Jul 8;11:667148. doi: 10.3389/fonc.2021.667148. PMID: 34307137; PMCID: PMC8296820.
9. Zhu G, Huang H, Xu S, Shi R, Gao Z, Lei X, Zhu S, Zhou N, Zu L, Mello RA, Chen J, Xu S. Prognostic value of ferroptosis-related genes in patients with lung adenocarcinoma. Thorac Cancer. 2021 Jun;12(12):1890-1899. doi: 10.1111/1759-7714.13998. Epub 2021 May 12. PMID: 33979897; PMCID: PMC8201541.
10. Zhu G, Ren D, Lei X, Shi R, Zhu S, Zhou N, Zu L, Mello RA, Chen J, Xu S. Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer. Cancers (Basel). 2021 Mar 19;13(6):1397. doi: 10.3390/cancers13061397. PMID: 33808631; PMCID: PMC8003499.
11. Zhu S, Zhao S, Zhang Q, Li S, Ren D, Ren F, Zu L, Wang Y, Lei X, Zhou N, Shi T, Xu D, Chen G, Lim WT, Giusti R, Wu AJ, Xu S. Complete disease remission in a TP53 and KRAS co-mutated brain oligometastatic lung cancer patient after immuno-chemotherapy and surgical resection: a case report. Transl Lung Cancer Res. 2021 May;10(5):2298-2305. doi: 10.21037/tlcr-21-380. PMID: 34164277; PMCID: PMC8182723.
12. Shi T, Zhu S, Guo H, Li X, Zhao S, Wang Y, Lei X, Huang D, Peng L, Li Z, Xu S. The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures. Front Oncol. 2021 Feb 23;11:567978. doi: 10.3389/fonc.2021.567978. PMID: 33708622; PMCID: PMC7940546.
13. Zhao S, Li S, Liu W, Wang Y, Li X, Zhu S, Lei X, Xu S. Circular RNA Signature in Lung Adenocarcinoma: A MiOncoCirc Database-Based Study and Literature Review. Front Oncol. 2020 Oct 9;10:523342. doi: 10.3389/fonc.2020.523342. PMID: 33163392; PMCID: PMC7581697.